Ascentage Pharma Group International (AAPG) Presents at Citi’s Biopharma Back

John Whittaker

Okay. Nice to see everyone here in the room today. I’m John Whittaker with the Citi Investment Banking team. Excited to have a discussion with Ascentage here this afternoon. And Veet, obviously, you’re new to the sea. Congratulations. And I think it would be helpful, certainly introduce yourself. And I think it would be helpful to provide a bit of a background on Ascentage. The company overall. And obviously, you just had your first half update a couple of weeks ago and highlighted some key progress and milestones to be attentive to on the horizon.

So maybe take a couple of minutes to talk about the company and some of your key updates from August.

Veet Misra
Chief Financial Officer

Yes, sure. Thank you, John. Thank you for having me. Happy to do that. Yes, so I joined Ascentage as a CFO a couple of months ago, beginning of July. Been a couple of months, but it feels like it’s been a couple of years’ worth of activity. So very — maybe I can start by talking about the innovative pipeline that we have.

As it relates to the company now, we have 2 differentiated novel oncology products now being sold in China. So our first asset, olverembatinib is a third-generation BCL BCR-able TKI. So this is a very important area where the company got — initially, it got what’s known as conditional approval in China about — in 2021. So this is very much like accelerated approval in the U.S. And eventually, the company got full approval and importantly, for both patients with or without mutations.